Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. The company's management team is scheduled for a fireside chat on Wednesday, September 4th at 1:05 PM ET.
Investors and interested parties can access a live audio webcast of the event, as well as an archived recording, through the "Events and Publications" tab on the investor relations section of Centessa's website at https://investors.centessa.com/events-presentations. This participation provides an opportunity for Centessa to showcase its progress in discovering and developing transformational medicines for patients.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CNTA gained 1.58%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody technology platform. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
When is Centessa Pharmaceuticals (CNTA) participating in the Morgan Stanley Healthcare Conference?
How can investors access Centessa Pharmaceuticals' (CNTA) presentation at the Morgan Stanley conference?
What type of company is Centessa Pharmaceuticals (CNTA)?
Where is the Morgan Stanley 22nd Annual Global Healthcare Conference being held?
